Litigation Details for CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (D.N.J. 2019)
✉ Email this page to a colleague
CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (D.N.J. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-10-07 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | |
| Jury Demand | None | Referred To | |
| Patents | 10,010,537; 8,658,676 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Biologic Drugs cited in CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for CHIESI USA, INC. v. AUROBINDO PHARMA USA, INC. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-10-07 | 1 | (3) patents as covering Chiesi’s Cleviprex®: the ’676 patent, the ’537 patent, and U.S. Patent No. 5,856,346…involving U.S. Patent No. 8,658,676 (“the ’676 patent”) (attached as Exhibit A hereto) and U.S. Patent No. 10,010,537…expiration dates of the patents in suit: the ’676 patent and the ’537 patent. As indicated in the Orange…Orange Book, the patent expiration for the ’676 patent and the ’537 patent is October 10, 2031. …the ’676 patent and the ’537 patent were submitted to FDA with NDA No. 022156. The ’676 patent and the | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
